Replies to post #4594 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Chaos Theory: The Butterfly Effect

The butterfly effect is a phenomenon which has evolved from the Chaos Theory. In metaphorical language, it means that a small change can give rise to a big tidal wave. ... He concluded that a simple movement like that of a flapping of a wing by a butterfly gives rise to a tornado somewhere else

.
There is no doubt Breathtec shares the exact same technology as Cannabix. There is no doubt speculation over the years have pushed the technology to a value of nearly $300M USD. There is no doubt in my mind the FAIMS technology @ Breathtec is insanely undervalued given the fact I believe Breathec's RUO device and Cannabix's THC Breathalyer are on the exact same timeline for completion. Both devices are being developed by Dr. Frost (Yost).

The Research Use Only Roadmap in Black and White (Excerpts):

The Company announces that it has amended its research agreement with the University of Florida’s Analytical Chemistry Department, where Dr. Richard Yost, the Principal Investigator, will work to advance the V3 prototype, or future iterations, through its final stages of prototype development. Dr. Yost is one of the world’s foremost experts on FAIMS technology and has been a scientific advisor with the Company since 2016.

...Once the prototype work is completed, the device will be ready to be moved into a research use only (RUO) development phase. The goal of this phase will be to engineer and produce field ready devices that will be made available to research scientists worldwide to help advance the discovery and validation of breath-based biomarkers.

It is generally regarded within the global breath research community, that a portable, point of care breathalyzer device, that can accurately identify and quantify biomarkers in real-time, could dramatically enhance and improve the current research landscape. This advancement could possibly lead the way to regulatory approved testing.

To date, the MistyWest story is also Breathtec's story. Is it not obvious Breathtec will also benefit from the Breath Collection Unit (BCU)/$-ame $-hared technology? Meanwhile, on The Darkside of Breathtec's Moon there's Nash Pharmaceuticals. Nash Pharma is aggressively positioning itself firmly within the race to cure Nash disease. As Smoki once stated here in so many words...the name "Nash Pharmaceuticals" alone could be worth a US Mint wrapped in Gold - Fort Knox.

The $35 billion race to cure a silent killer that affects 30 million Americans

Since the signing of Nash Pharmaceuticals from October 2018, there has been 12 New Releases. That's called being - On A Tear! Long's have long ago wrapped themselves up in a cocoon to painstakingly endure several silly seasons of uncertainty. Given the facts @ hand, the month of February 2019 may be the breakout season longs have longed for.

“The NASH market segment represents an enormous unmet medical need globally and there is a particular interest in compounds exhibiting anti-fibrotic activity,” said Christopher J. Moreau CEO of Nash Pharma. “We plan to present our preclinical in vivo NASH results at the upcoming 2nd Global NASH Congress, in February 2019 in London, UK and have now begun preparations to start a Phase IIa study for our repurposed lead candidate NP-160 in 2019.”

The Butterfly Effect



/////AMG